Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2024-04-26 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled "内部控制审计报告" which translates to "Internal Control Audit Report." It includes detailed audit opinions on the effectiveness of the company's internal control over financial reporting as of December 31, 2023. The text references auditing standards, responsibilities of the board and auditors, and detailed internal control evaluation criteria and conclusions. It is issued by a certified public accounting firm with official registration and certification details. The document contains substantive audit content and evaluation results rather than just an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. The document is not an Annual Report (10-K) or Interim Report (IR) as it focuses solely on internal control audit results. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains the full audit report text and detailed findings, not just a notice or certification. Therefore, the correct classification is AR with high confidence.
2024-04-26 Chinese
赛伦生物：2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度会计师事务所履职情况评估报告' which translates to '2023 Annual Evaluation Report on the Performance of the Accounting Firm'. It details the evaluation of the audit firm's performance during the 2023 audit of the company. The content focuses on the audit firm's qualifications, resources, audit plan, quality management, and overall evaluation of their audit work. It does not contain the company's financial statements or full financial performance data, but rather an assessment of the audit process and the auditor's conduct. This matches the description of an Audit Report / Information (AR), which includes standalone audit reports and evaluations related to auditing, excluding full annual reports. The document length is 2641 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-26 Chinese
赛伦生物：2023年度独立董事述职报告（傅以尚）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, independence, attendance at meetings, communication with audit and management, oversight of financial reports, and other governance-related activities during the year 2023. The content focuses on the independent director's duties and evaluation of company governance and financial reporting compliance. It is not a full annual report, audit report, or financial statement, but rather a management/governance-related report by an independent director. This fits best under Board/Management Information (MANG) as it relates to board member duties and disclosures. The document length is 2687 characters, which is relatively short and consistent with a director's report rather than a full financial report. Therefore, the classification is MANG with high confidence.
2024-04-26 Chinese
赛伦生物：2024年度”提质增效重回报”行动方案
Regulatory Filings Classification · 95% confidence The document is titled as a 2024 annual action plan by Shanghai Sairen Biotechnology Co., Ltd., focusing on operational improvements, governance, investor relations, and shareholder returns. It outlines strategic initiatives, governance enhancements, investment plans, and dividend policies. The document is relatively short (3726 characters) and reads like a corporate announcement or plan rather than a full financial report with detailed financial statements or comprehensive analysis. There is no indication of detailed financial data, audit opinions, or regulatory certifications. It also does not appear to be a notice of voting results, a call transcript, or a legal proceeding update. The content is more aligned with a corporate strategic plan or operational update. Given the length and content, it fits best as a Regulatory Filing (RNS) because it does not meet the criteria for a full Annual Report (10-K), Interim Report (IR), or other specific report types. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability.
2024-04-26 Chinese
赛伦生物：2023年度独立董事述职报告（叶榅平）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 from Shanghai Sairen Biotechnology Co., Ltd. It details the independent director's background, duties performed, attendance at meetings, communication with audit and management, and oversight activities during the year. The content focuses on the director's role and activities rather than financial results or company-wide annual performance. It is a report on the independent director's duties and observations rather than a full annual report or audit report. This type of document is typically classified under Board/Management Information (MANG) as it relates to governance and management oversight rather than financial reporting or shareholder voting results. The document length is 2550 characters, which is relatively short and focused on director duties, supporting this classification. Therefore, the best fit is MANG with high confidence.
2024-04-26 Chinese
赛伦生物：2023年度独立董事述职报告（刘军岭）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 from Shanghai Sairen Biotechnology Co., Ltd. It details the independent director's duties, attendance at board and shareholder meetings, communication with audit and accounting firms, and oversight activities during the year. It includes information about board appointments, remuneration review, and compliance with legal and governance standards. The document is a detailed report on the independent director's activities and oversight for the year, not a general annual report or financial statement. It is not a simple announcement or certification but a substantive report on board/management information, specifically about independent director duties and activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters but contains detailed content, so it is not a mere announcement (RPA) or regulatory filing (RNS).
2024-04-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.